Dirk Demuth

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Brian Bressler, Andrés Yarur, Mark S. Silverberg et al. · Journal of Crohn s and Colitis · 2021 · 147 citations · Full text

Pharmacy, Pharmacotherapy, Gastrointestinal Pharmacotherapy +16

The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD)

Christopher Kingswood, Patrick Bolton, Pamela Crawford et al. · European Journal of Paediatric Neurology · 2015 · 98 citations · Full text

Medicine, Neurology, Neuropathology +4

Knowledge, Attitudes and Practices toward Dengue Fever, Vector Control, and Vaccine Acceptance Among the General Population in Countries from Latin America and Asia Pacific: A Cross-Sectional Study (GEMKAP)

Asrul Akmal Shafie, Edson Duarte Moreira, Alberta Di Pasquale et al. · Vaccines · 2023 · 51 citations · Full text

Medicine, Health Behavior, Health Education +17

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

Rupa Banerjee, Sai Wei Chuah, Ida Hilmi et al. · Intestinal Research · 2020 · 22 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study

Jesús K. Yamamoto‐Furusho, Othman Al Harbi, Alessandro Armuzzi et al. · Digestive and Liver Disease · 2020 · 20 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +10